Navigation Links
Study Funded by National Foundation for Cancer Research Reveals Imaging Studies May Predict Tumor Response to Anti-Angiogenic Drugs
Date:11/23/2013

Bethesda, MD (PRWEB) November 23, 2013

A new report published in the Proceedings of the National Academy of Science (PNAS) Early Edition details a study funded in part by the National Foundation for Cancer Research, which indicates magnetic resonance (MR) imaging may be able to discern which patients will benefit more from anti-angiogenic drugs.

An NFCR Fellow, Rakesh K. Jain, Ph.D., is a senior author of the study and the director of the Steele Laboratory for Tumor Biology in the MGH Department of Radiation Oncology.

The just-released study shows that cancer patients with glioblastoma—the deadliest form of brain tumor— survived longer with the increased level of blood perfusion due to the anti-angiogenic agent cediranib. The level of blood perfusion was revealed using advanced brain imaging called vessel architectural imaging (VAI) and other MR imaging techniques.

This study also confirms the hypothesis Dr. Jain proposed more than a decade ago on how anti-angiogenic drugs work. These drugs enhance the activity of chemo- and radiation therapy, yet the mechanisms of their action remain unclear. Results from the study suggest that, rather than 'starving' tumors by choking their blood supply as scientists originally thought, it appears that anti-angiogenic drugs actually work through “normalizing” the abnormal, leaky blood vessels that surround the tumors. This normalization process may improve the delivery of chemotherapy drugs and the oxygen that is required for effective radiation therapy.

“This study is a turning point, as it is the result of a decade-long journey towards the confirmation that vascular normalization actually increases tumor perfusion and that increased perfusion, rather than tumor starvation, increases the likelihood of survival,” said Dr. Jain. “I am honored to be a part of this research and NFCR’s pursuit of more effective treatments for glioblastoma patients.”

“NFCR is proud to support this leading-edge research that will help increase survival rates among glioblastoma patients,” said Franklin Salisbury, Jr., President of NFCR. “Being able to improve the effectiveness of treatments for cancer patients is a stepping stone on the way towards finding a cure.”

To read the report and find out more about the study’s implications, please visit http://www.pnas.org/content/early/2013/10/31/1318022110.full.pdf+html.

About the National Foundation for Cancer Research
The National Foundation for Cancer Research (NFCR) is a leading cancer research charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, a cure for cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside.

Since 1973, NFCR has provided over $309 million supporting discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. For more information, please visit http://www.NFCR.org.

###

Read the full story at http://www.prweb.com/releases/2013/11/prweb11364428.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study looks at better prediction for epileptic seizures through adaptive learning approach
2. Kessler Foundation study provides first Class 1 evidence for cognitive rehabilitation in MS
3. Study shows displaying lab costs upfront can save money
4. HIV and parenting needs to be discussed, new study finds
5. New Results from an Orriant Study Illustrate Drastic Improvements Both Physically and Financially
6. Fertility Centers of Illinois is Recruiting Patients for The MultiCenter Registry with Eeva™ (MERGE) Research Study
7. Study reveals higher levels of control and support at work increases wellbeing
8. Blood vessel tangles in brain best left alone, study suggests
9. "Taking Timeout from Technology" Study Results Announced by The Unplug Series, Shows 20% Would Suffer Withdrawal Symptoms After 24 Hours
10. New Study Improves Understanding of Tinnitus Perception by Patients
11. New study finds no benefit to selecting dose of blood thinner based on patients genetic makeup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: